Drug
Sitagliptin (DPP4 inhibitor)
Sitagliptin (DPP4 inhibitor) is a pharmaceutical drug with 4 clinical trials. Currently 1 active trials ongoing. Historical success rate of 100.0%.
Total Trials
4
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 1 completed trials
Completion Rate
100%(1/1)
Active Trials
1(25%)
Results Posted
100%(1 trials)
Phase Distribution
Ph phase_1
2
50%
Ph not_applicable
1
25%
Ph phase_4
1
25%
Phase Distribution
2
Early Stage
0
Mid Stage
1
Late Stage
Phase Distribution4 total trials
Phase 1Safety & dosage
2(50.0%)
Phase 4Post-market surveillance
1(25.0%)
N/ANon-phased studies
1(25.0%)
Highest Phase Reached
Phase 4Trial Status & Enrollment
Completion Rate
100.0%
1 of 1 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
1
trials recruiting
Total Trials
4
all time
Status Distribution
Active(3)
Completed(1)
Detailed Status
Not yet recruiting2
Completed1
Recruiting1
Development Timeline
Analytics
Development Status
Total Trials
4
Active
1
Success Rate
100.0%
Most Advanced
Phase 4
Trials by Phase
Phase 12 (50.0%)
Phase 41 (25.0%)
N/A1 (25.0%)
Trials by Status
completed125%
not_yet_recruiting250%
recruiting125%
Recent Activity
1 active trials
Showing 4 of 4
not_yet_recruitingphase_4
Comparative Study Between (SGLT-2i) and (DPP-4i) in the Prevention of DIC
NCT07436663
recruitingphase_1
Triple Hypoglycemic Regimens In Patients With Newly Diagnosed Type 2 Diabetes Mellitus
NCT07374328
not_yet_recruitingphase_1
Neoadjuvant Chemotherapy, Anti-PD-1 Antibody and Sitagliptin for Locally Advanced pMMR CRC
NCT07365592
completednot_applicable
Pharmacogenetics of Ace Inhibitor-Associated Angioedema
NCT01413542
Clinical Trials (4)
Showing 4 of 4 trials
NCT07436663Phase 4
Comparative Study Between (SGLT-2i) and (DPP-4i) in the Prevention of DIC
NCT07374328Phase 1
Triple Hypoglycemic Regimens In Patients With Newly Diagnosed Type 2 Diabetes Mellitus
NCT07365592Phase 1
Neoadjuvant Chemotherapy, Anti-PD-1 Antibody and Sitagliptin for Locally Advanced pMMR CRC
NCT01413542Not Applicable
Pharmacogenetics of Ace Inhibitor-Associated Angioedema
All 4 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 4